Spots Global Cancer Trial Database for A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

Official Title: A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

Study ID: NCT04761744

Conditions

DDR Gene Mutation

Metastatic Solid Tumor

Interventions

Nivolumab

Study Description

Brief Summary: A Phase II Study of Nivolumab in Patients with Genetic alterations in DNA Damage repair and response Who Progressed after Standard treatment for Metastatic Solid Cancers

Detailed Description: All the patients will be included in the final analysis, with a total of 48 patients to be enrolled. Treatment will occur until disease progression, unacceptable toxicity or patient withdrawal. Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks. Response evaluation will be performed every 6 weeks (+/- 1 week window period is allowed).